MPharma 's cross-border play under AfCFTA
What the move actually costs — and the plays a founder can borrow.
- How Zambia's market shapes the outcome.
- The practical move an operator can make this quarter.
- What to watch next as the story develops.
What the move actually costs — and the plays a founder can borrow.
- How Zambia's market shapes the outcome.
- The practical move an operator can make this quarter.
- What to watch next as the story develops.
For anyone building in trade & industry, the useful question is where this changes your costs, distribution or competition — and how soon you act on it.
AI-generated summary. It can miss nuance — read the full story above for the complete picture.
mPharma has moved again — and for founders across Zambia, the details matter more than the headline.
The team's bet is simple: expand into three new markets without burning the runway that Sequoia just extended.
Why it matters
In this economy, unit economics are the strategy.
The move reframes cash flow for anyone building in Zambia: get the fundamentals right before you scale.
Competitors won't sit still. Expect global players to respond within the quarter.
What to watch next
- How Zambia's regulators respond over the next two quarters.
- Which rivals move first, and how global players counter.
- Whether the growth round buys enough runway to reach the next milestone.
For now, mPharma has bought itself time — and a story worth studying.
